Clinical Trial Update: Effect Of Probiotic Lactobacillus Paracasei Lp-33 For The Management Of Rhinitis In People Sensitized To Allergens [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the probiotic Lactobacillus paracasei Lp-33 for managing allergic rhinitis in individuals sensitized to allergens has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Lactobacillus paracasei Lp-33 (Lactobacillus paracasei Lp-33)

Snippet

Sponsor: Merck Medication Familiale | Conditions: Rhinitis | Phase 3 | Status: COMPLETED